Trial · NCT02819843

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

NCT02819843, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2025-01-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors. Trials, record NCT02819843. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02819843

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
NCT number: NCT02819843
Status: Completed
Phases: Phase 2
Enrollment: 19 participants, actual
Lead sponsor: Memorial Sloan Kettering Cancer Center
Conditions: Melanoma, Merkel Cell Carcinoma, Other Solid Tumors
Interventions: TALIMOGENE LAHERPAREPVEC (TVEC), Hypofractionated Radiotherapy
First posted: 2016-06-30
Last updated: 2025-01-29
Results first posted: 2025-01-29

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Best Response	16 weeks	Overall subject level response is defined as partial or complete (\>50% or greater decrease in largest lesion) by the modified World Health Organization (mWHO) criteria, and will include measurements of tumor size by CT component of PET/CT, and clinically by digital photography.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Best Response	16 weeks		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Best Response	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	Complete Response	1	Participants
Best Response	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	Complete Response	1	Participants
Best Response	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	Partial Response	0	Participants
Best Response	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	Partial Response	0	Participants
Best Response	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	Stable Disease	2	Participants
Best Response	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	Stable Disease	5	Participants
Best Response	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	Progressive Disease	6	Participants
Best Response	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	Progressive Disease	4	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	9
Overall Study	STARTED	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	10
Overall Study	COMPLETED	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	9
Overall Study	COMPLETED	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	9
Overall Study	NOT COMPLETED	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	0
Overall Study	NOT COMPLETED	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	1

Source ClinicalTrials.gov

Adverse events20

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Fever	General disorders	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	5	9
other	Fever	General disorders	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	3	10
other	Fatigue	General disorders	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	2	9
other	Fatigue	General disorders	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	3	10
other	Chills	General disorders	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	2	9
other	Chills	General disorders	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	5	10
other	Vomiting	Gastrointestinal disorders	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	1	9
other	Vomiting	Gastrointestinal disorders	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	1	10
other	Dyspnea	Respiratory, thoracic and mediastinal disorders	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	0	9
other	Dyspnea	Respiratory, thoracic and mediastinal disorders	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	1	10

1 to 10 of 20Source ClinicalTrials.gov

See all 20 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	8	9
Total, all-cause mortality	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	9	10
Total, other adverse events	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	9	9
Total, other adverse events	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	10	10
Total, serious adverse events	Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy	0	9
Total, serious adverse events	Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy	0	10

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy vs Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy: deaths from any cause	Trial comparisons
Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy vs Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02819843

GET https://conductscience.org/api/trials/v1/NCT02819843/registered

API reference For AI assistants